After screening 8 469 articles, we included two randomized controlled trials and one open-label study, in which a total of 426 patients were enrolled. Cannabinoids relevantly decreased the number of incontinence episodes in all three studies.
Introduction
Neurogenic lower urinary tract dysfunction (NLUTD) is highly prevalent in people with multiple sclerosis (MS) and substantially impairs quality of life [1, 2] . The prevalence of NLUTD appears to be related to the duration of MS and is reported by almost all patients who have MS for >10 years [1, 3] . Treatment of NLUTD in the population with MS is a significant challenge, especially because standard therapies often fail. Therapeutic alternatives are therefore urgently needed.
Cannabinoids, a heterogenous group of endogenous molecules and others that are metabolites of phytocannabinoids [4] , have been reported to improve tremor and spasticity in animal models [5] and questionnaire-based reports have suggested beneficial effects of recreational cannabis use in patients with MS who have NLUTD [6] . Cannabinoids are presumed to reduce detrusor contractility via cannabinoid receptors [7, 8] expressed both in the detrusor and CNS [9] ; however, cannabinoid-mediated actions on lower urinary tract function are complex and not yet fully understood. Considering the potential of cannabinoids for medical use [10] , we performed a systematic review to assess and appraise the evidence on efficacy and safety of cannabinoids in the treatment of NLUTD in patients with MS.
Evidence Acquisition

Data Sources and Searches
The present systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement [11] . A review protocol was elaborated, which is available on PROSPERO (CRD42014010142) (http://www.crd.york.ac.uk/PROSPERO). We searched the Cochrane Central Register of Controlled Trials, Embase, Medline and Scopus systematically for studies published between 1 January 1946 and 11 November 2016. No language restriction was applied. In addition, we searched the reference lists of all included studies and any relevant review articles. In addition, on 23 November 2016, we searched for unpublished (ongoing) research at ClinicalTrials.gov and the ISRCTN registry, but no additional studies were identified. The search strategies are shown in Fig. S1 .
Study Selection
We aimed to include all original studies that reported efficacy and/or safety data on cannabinoids for treating NLUTD in women and men with MS, including randomized controlled trials (RCTs), comparative non-RCTs, and single-arm cohort studies. Non-original articles, those including children only, and those not discriminating between patients with MS and other neurological/non-neurological disorders were excluded. All identified abstracts were imported into bibliography management software (EndNote X7; Thomson Reuters, Philadelphia, PA, USA) and filed according to inclusion and exclusion folders by drag and drop. Abstracts of all identified studies were independently reviewed by three authors (N.A.Y., M.P.S. and L.M.). Studies reporting on cannabinoids for treating NLUTD in patients with MS were reviewed in full text.
Data Extraction and Risk of Bias Assessment
The variables assessed included year of publication, type of study, type of cannabinoid, type of combination of cannabinoid, treatment duration, number of patients, gender and age, improvement of incontinence and nocturia episodes, number of daytime voids, adverse events and withdrawals. Data from eligible reports were extracted in duplicate (N.A.Y. and M.P.S.) and discrepancies were resolved by a third reviewer (T.M.K.).
The Cochrane Risk of Bias Assessment tool was used for RCTs [12] . This included the assessment of sequence generation, allocation concealment, blinding of participants, therapists and outcome assessors, completeness of outcome data, and selective outcome reporting (Fig. S2) . The risk of bias in the comparative non-RCT was assessed using the Cochrane tool and an extra item to estimate the risk of findings being explained by confounding (Fig. S2 ). This is a pragmatic approach recommended in the methodological literature to assess risk of bias in non-randomized studies [13] [14] [15] . A list of the five most important confounders for efficacy and safety outcomes was developed with clinical content experts (members of the International Continence Society Neuro-Urology Promotion Committee). The confounding factors were gender, age, UTIs, degree of disability (Expanded Disability Status Scale/duration of neurological disease) and other medications. In addition, external validity was taken into account by assessing whether study participants were selected consecutively and whether the specified confounding factors were similar in each treatment group. Attrition bias and selective outcome reporting were also assessed (Fig. S2) . This is also a pragmatic approach informed by the methodological literature [12] .
Finally, conflict of interest declarations, reporting of funding sources and role of any funding sources was investigated.
Data Synthesis
We constructed two-by-two tables for each of the included studies and calculated the effect size and corresponding 95% CIs. Because data were sparse, we performed only an exploratory analysis, ignoring differences in study design. The missing control group from the open-label study was replaced by a norm-control group, generated by the mean values of the two control groups from the RCTs. We pooled the effect size using a random effects model. Forest plots were generated to provide a visual representation of results and to illustrate the direction and magnitude of effects. Analyses were performed using the metan command of the STATA statistics software package (STATA 14.0 and 9.0 statistics software package; [16] ).
A risk of bias summary and graph ( Fig. S2 ) was generated using Cochrane REVMAN software (REVMAN version 5.3; Informatics and Knowledge Management Department; Cochrane, London, UK).
Evidence Synthesis
Search Results
The PRISMA flow diagram chart ( Fig. 1) shows the literature search and results. After screening of 8 469 abstracts, three studies were included in the qualitative and quantitative synthesis.
Study and Patient Characteristics
Two of the three included studies were RCTs [17, 18] and one was an open-label study [19] . Overall, the three included studies enrolled a total of 426 patients: 289 women (68%), 122 men (29%) and 15 patients (3%) for whom gender was not reported. The study by Brady et al. [19] was an openlabel study with a two-phase follow-up: initial combination therapy with delta-9-tetrahydrocannabinol (THC) and cannabidiol for 8 weeks, followed by a single THC-only therapy for further 8 weeks (Table 1) .
Efficacy of Cannabinoids
Cannabinoids relevantly decreased incontinence episodes in all three studies (Table 2) . Pooling data showed the mean difference in incontinence episodes per 24 h to be À0.35 (95% CI À0.46 to À0.24; Fig. 2 ). In addition, a significant decrease in number of nocturia episodes, daytime voids and voids per 24 h was found in one study ( Table 2) .
Safety of Cannabinoids
The most common adverse events are shown in Table 1 . The general number of mild adverse events was high (38-100%), but only two patients (0.7%, 2/277 patients) reported a serious adverse event (one haemorrhagic cystitis and one possible transient ischaemic attack, both with unclear causality).
Risk of Bias and Confounding
The risk of bias and confounding was high in the non-RCT (Fig. S2) [19] .
Conflict of Interest, Funding Source and Role of Funding Source
A conflict of interest was only disclosed by Kavia et al. [17] . Non-company funding was reported by Brady et al. [19] and Freeman et al. [18] , whereas the study by Kavia et al. [17] was fully funded by the manufacturing company. None of the studies reported on the role of the funding source in the study.
Discussion
Principal Findings
Improvements in incontinence rates, nocturia, daytime and 24-h voids, as well as a limited number of severe adverse events, suggest that cannabinoids may be effective and safe for treating NLUTD in patients with MS. Although our findings are promising, the evidence in the present systematic review was confined to three studies with a very limited overall number of treated patients.
Findings in the Context of Existing Evidence
The endocannabinoid system is involved in regulation of lower urinary tract function, possibly at several levels of the micturition pathway [9] . Studies in experimental animal models have demonstrated the role of cannabinoid receptors in sensory signalling and afferent bladder functions, as well as a possible modulatory effect on cholinergic nerves [20] . Fatty acid amide hydrolase, which degrades endocannabinoids and fatty acid amides, is present both in the bladder mucosa and the CNS, controlling lower urinary tract function. Inhibition of fatty acid amide hydrolase in rat models has been shown [9, 21] .
Cannabis is one of the most popular recreational drugs worldwide and it is speculated that 178 million people in the age group 15-64 years used it at least once in the year 2012 [10] . There are~60 pharmacologically active compounds extracted from the marijuana plant and the most popular is THC, with psychoactive effects that are related to the concentration in the applied preparation [22] . Because of the delay in onset of effect and narrow therapeutic window with resultant predilection for adverse effects, THC is administered in combination with another phytocannabinoid, such as cannabidiol [23] . Over the years, there has been a growing interest in the medical use of cannabis in treating disease and alleviating symptoms. Summarizing RCTs to assess the benefits and adverse events of cannabinoids, indicates that there is moderate-quality evidence supporting prescription cannabinoids as an effective and safe treatment of chronic neuropathic or cancer pain, sleep disorders and spasticity attributable to MS [10, 24] ; however, statistical significance was not reached in any of the clinical trials. Nevertheless, cannabinoids are particularly interesting because of the favourable safety profile as severe side effects are very rare.
Implications for Research
Prescription cannabinoids are becoming a well-established pharmacological treatment for pain and other diseases, with a favourable safety profile [10] . The preliminary data summarized in the present systematic review suggest potential benefits of cannabinoids for treating NLUTD in both women and men with MS and, therefore, further clinical trials are warranted. Appropriately designed multicentre RCTs are necessary to assess validated disease-and condition-specific quality-of-life data, urodynamic findings, short-, mediumand long-term outcomes, and safety, as well as costeffectiveness issues.
Despite many animal studies on cannabinoids and their function, the mechanism of action is not yet fully understood and, in particular, the effects of cannabinoids for treating NLUTD remain to be elucidated. Further animal studies addressing the potential mechanism of action of cannabinoids for treating NLUTD are therefore warranted.
Implications for Practice
The progressive nature of the course of disease in MS influences NLUTD and thereby the effect of therapy [1] ; thus, cannabinoids might be successful at the beginning in a patient with MS but lose efficacy as the disease progresses. Nevertheless, cannabinoids open another therapeutic avenue for managing NLUTD in patients with MS. The safety profile is favourable and cannabinoids are devoid of the adverse effects, such as blurred vision or constipation, associated with other more commonly used agents, which are particularly relevant in patients with neurological disease. Moreover, this treatment is not associated with a risk of voiding dysfunction, in contrast to most of the other therapeutic options, and is particularly attractive to patients with MS where catheterization and associated complications are a real concern. The GP and/or neurologist may initiate the neurourological treatment, considering that the risk of developing upper urinary tract damage and renal failure is much lower in patients with slowly progressive non-traumatic neurological disorders such as MS and Parkinson's disease than in those with spinal cord injury or spina bifida [1] . The treatment goals of cannabinoids vary between different neurological disorders. Thus, dose-and disease-specific studies are warranted, and continuous vs on-demand medication has to be further assessed. In addition, cannabinoids might be considered as a treatment to improve different quality-of-life issues of the patient with MS including NLUTD. Taking into account the potential of cannabinoids in medical use [10] , it seems worth trying them before more invasive treatments are established.
Limitations of the Present Review
Although the present report represents, to the best of our knowledge, the first study to review and synthesize systematically all available evidence of cannabinoids for treating NLUTD in patients with MS, there are limitations that should be addressed. The number of included articles, the number of investigated patients and the follow-up were very limited. Moreover, the severity of MS and NLUTD were not reported. In addition, the missing control group in the open-label study was replaced by a norm-control group generated by the mean values of the two control groups from the RCTs for statistical analysis. In the absence of robust evidence there is a trade-off between the level of methodological rigor of an analysis and its efficiency. Using the base rate of the two RCTs allowed us to incorporate the single-arm study. In view of the fact that any results derived from two or three studies will be exploratory, we decided to use this approach. Standard deviations for baseline and follow-up measurements were missing in most outcome measures and heterogeneity among the studies was substantial. More detailed methodological study limitations are described in Fig. S3 .
Conclusions
The currently available evidence implies that cannabinoids may be effective and safe for treating NLUTD in patients with MS; however, although we identified two RCTs, the reported outcomes, number of investigated patients and follow-up were very limited and the study heterogeneity was substantial; therefore, the present systematic review, although suggesting that treatment with cannabinoids is a promising option for NLUTD in patients with MS, shows the urgent need for well-designed, adequately sampled and powered RCTs to reach definitive conclusions. interpretation of the data, preparation, review or approval of the manuscript or the decision to submit the manuscript for publication.
